Unimed Medical Center
Abovyan, Yerevan, 0001, Armenia
NCT Number: NCT04183842
The primary objective of the study is to test whether the tested Product LACIME Anti-hangover is effective in preventing the signs and symptoms of alcohol-induced hangover (such as headache, impaired memory, depression, anxiety, weakness, trouble sleeping and concentrating, nausea, dizziness, sleepiness, thirsty, dry mouth, sweating, sensitivity to light and sounds, vision problems) in healthy subjects.
Looking for future studies?
Notify Me20 year–30 year
Male
Interventional
Not applicable
Abovyan, Yerevan, 0001, Armenia
LACIME Anti-hangover is a food supplement under the form of a syrup (water/glycerin based) containing plan extracts, each one having choleretic properties.
40 healthy subjects will be tested in a randomized, double-blind, placebo-controlled, crossover trial.
The participants will have to attend the 2 phases of the study during which they will receive in a blind way a product (LACIME Anti-hangover or PLACEBO):
If a participant has received LACIME Anti-hangover for Phase 1, the same participant will receive the PLACEBO for Phase 2 and vice versa.
Inclusion criteria
For inclusion in the study subjects must fulfil all the following criteria:
20-30 years old healthy males and females, Body weight (kg): 60 - 80 in man and 60-70 in women, People who consume alcohol occasionally and who already have to deal with hangovers Healthy volunteers who consume alcohol regularly and moderately, Having given their free, informed and express consent in writing Co-operative, informed of the need and duration of the controls which make it possible to achieve full adherence to the protocol in place.
Exclusion criteria
Excluded from participating in the study:
Volunteers consuming larger amounts of alcohol (more than 2 glasses of alcohol per day) Volunteers taking medication or food supplements that may affect alcohol metabolism.
Women who are pregnant or breastfeeding or plan to become pregnant during the study Subjects with illnesses which may conflict with the investigator's interpretation, if the subject participated in the study Subject planning to change his/her lifestyle during the study (diet, physical activity, etc.) Smoker Subject participating in another study during the clinical study period.
Then participants take the Product LACIME Anti-hangover or PLACEBO and after 1hour will start to consume alcohol during two hours with meal (3 sandwiches with cheese or ham) on each of the 2 study phases.
Drink consumption, the composition and sequence:
300 ml of Brandy (41% vol. alcohol) corresponding to an intake of 123 ml or 99 g of alcohol 300 ml of Champagne (13% vol. alcohol) corresponding to an intake of 40 ml or 32 g of alcohol This will ensure a 100% hangover syndrome and a total intake of 131 g of alcohol (a dose of approximately 2 g / kg).
Such a dose will provide a peak concentration after 1 hour and should allow to determine the alcohol 15 hours after absorption.
Smaller doses are usually not detectable after 10-12 hours. (Jones, 2008).
D2 test, blood sampling and urine sampling under medical control is achieved before alcohol intake.
D2 test, blood sampling and urine sampling under medical control is achieved 1h, 4h and 15h after alcohol consumption.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
LACIME Anti-hangover contains the following excipients:
LACIME Anti-hangover contains the following plant extracts and vitamin:
Placebo contains the following excipients :
Placebo contains :
Time frame: Total duration 2 days (Total=16h00: From 1h00 before alcohol intake until 15h after alcohol consumption)
Evaluation of the difference in Hangover Severity Scores between the activity of LACIME Anti-hangover and the activity of PLACEBO.
The measure is the true change in self assessment scores from their baseline. 12 self assessed parameters :
For each of the above symptoms, the Hangover Severity Scale ranges from 0 to 4.
The Scores are evaluated according to the following:
Self assessment is achieved:
Time frame: Total duration 2 days (Total=16h00: From 1h00 before alcohol intake until 15h after alcohol consumption)
The test "d2" consists of identifying and marking the letters "d" accompanied by two dashes only in the middle of other annoying characters.
The test "d2" is an array containing 14 lines of 47 characters which must all be checked.
The recorded figures are :
Three indices, reveal the evolution of the concentration:
Changes of psychometric parameters are evaluated by d2 test at:
Time frame: Total duration 2 days (Total=16h00: From 1h00 before alcohol intake until 15h after alcohol consumption)
Alcohol is mainly metabolized by hepatic oxydation by NADH / NAD+ enzymatic route.
Ingestion of Alcohol provoques an increase in the ratio NADH / NAD+ which disrupts all the other metabolic pathways in equilibrium with this coenzyme.
In the first stage of hepatic metabolism, the enzyme dehydrogenase converts alcohol into Acetaldehyde, a very toxic substance that has effects on the entire body.
Acetaldehyde is a choice marker to evaluate the level of alcoholic intoxication whenever it is an acute, massive or chronic absorption.
Titration of blood concentration of Acetaldehyde in mg/l
Changes of blood parameters from baseline are evaluated at:
Incara Lab
Industry
Evaluation of a Fixed Combination of Herbal Extracts to Prevent Symptoms Alcohol-induced Hangovers : A Randomized, Double Blind Placebo Controlled Crossover Study.
Acronym: LACIME
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06073886
Anxiety, Anxiety Disorders
Westwood, Los Angeles, California, United States
View Trial DetailsNCT01431326
Adenoviridae Infections, Adenovirus
Anchorage, Alaska, United States
View Trial DetailsNCT05708963
Back Pain, Behavior
New York, United States
View Trial DetailsNCT05326802
Back Pain, Behavior
New York, United States
View Trial Details